By: AllPennyStocks.com News

Tuesday, February 5, 2013

There are quite a few nutritional supplement companies trading on the over the counter markets, but many are struggling to get their products to market, nonetheless on the shelves of leading retailers. Even of the group that have achieved commercialization, the prospects can be few and far between for true micro-caps with growth potential in the near term. A compelling growth proposition worthy of further due diligence is Bond Laboratories, Inc. (OTCBB:BNLB) with its tiny $7.5 million market cap and full line of nutritional supplements that can be found in popular stores such as GNC (NYSE:GNC). The Omaha, Nebraska-based company develops and markets its products through its wholly-owned operating subsidiary, NDS Nutritional Products.

Bond and NDS made their splash in the industry with the introduction of Pump Fuel, a pre-workout supplement that has grown into a best seller at GNC over the past few years. A quick search around the web uncovers many faithful users of Pump Fuel and its offshoots Pump Fuel V2 and Pump Fuel Insanity that the company released in the second half of 2012.

Those few products are only a small portion of the 47 products in the NDS portfolio that have now penetrated more than 900 GNC franchise locations. The upside is that, while that is a robust number, there are still more than 1,600 GNC franchise locations across the globe that still aren’t carrying products manufacturing by NDS.

The growing number of products and shelf space are translating to higher revenue and profits for Bond. While investors should be on the lookout for figures from the fourth quarter and full year 2012 in the near term, operational performance for the third quarter and year-to-date was released last November showing significant expansion.

Compared to the same periods in 2011, third-quarter revenue increased by 43 percent to $4.6 million while nine-month revenue grew by 57 percent to $14.7 million. Net income for the third quarter was $500,000, compared to $300,000 during the year prior period. Through the first nine months of 2012, net income totaled $1.96 million or 2 cents per diluted share, versus $782,000, or 1 cent per diluted share in the first nine months of 2011.

On Tuesday, Bond Labs said that it has now launched a new weight loss product, called “EvoLean,” to its offerings through NDS.” The product will debut exclusively at GNC stores this week, according to a corporate statement.

“New product innovation is an integral part of our ongoing growth strategy and NDS has a long-standing tradition of developing high-quality dietary and nutritional supplements,” said John Wilson, chief executive at Bond Laboratories. “EvoLean’s low-stimulant formula boosts metabolism through a powerful blend of four key ingredients, which have been profiled and highly-touted on television by respected medical professionals,” he added.

Shares of BNLB have felt little impact to today’s news with only 28,000 shares in volume at about noon at a price of 10.5 cents, representing an increase of 4.5 percent over Monday’s closing price. Shares are up about 10 percent in the past 52 weeks and have a 52-week high of 13.85 cents last August. Additional due diligence is, as always, encouraged.

Copyright © 2013 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.